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Distinct patterns of soluble 
leukocyte activation markers 
are associated with etiology 
and outcomes in precapillary 
pulmonary hypertension
Tove Lekva1*, Lars Gullestad2,3,4, Kaspar Broch2, Pål Aukrust1,3,5,6, Arne K. Andreassen2 & 
Thor Ueland1,3,6
Activation of inflammatory processes has been identified as a major driver of pulmonary vascular 
remodeling that contributes to the development of precapillary pulmonary hypertension (PH). We 
hypothesized that circulating markers of leukocyte activation, reflecting monocytes/macrophages 
(sCD163, sCD14), T-cells (sCD25) and neutrophils (myeloperoxidase [MPO], neutrophil gelatinase-
associated lipocalin [NGAL]) activity, could give prognostic information in precapillary PH. Circulating 
markers of leucocyte activation, sCD163, sCD14, sCD25, MPO and NGAL were measured by enzyme 
immunoassays in plasma from patients with idiopathic PAH (IPAH; n = 30); patients with PAH related 
to associated conditions (APAH; n = 44) and patients with chronic thromboembolic PH (CTEPH) 
(n = 32), and compared with 23 healthy controls. Markers of leucocyte activation were elevated in 
precapillary PH with particularly high levels in APAH. The elevated levels of monocyte/macrophage 
marker sCD163 was independently associated with poor long-term prognosis in the group as a whole, 
and elevated levels of sCD25 was associated with poor prognosis in APAH, while elevated levels of 
sCD163 and NGAL was associated with poor prognosis in IPAH and CTEPH. Our data show leucocyte 
activation in precapillary PH with different profiles and impact on prognosis according to etiology. The 
association of sCD163 with poor outcome in fully adjusted model may be of particular interest.
Abbreviations
APAH  Associated pulmonary arterial hypertension
CTEPH  Chronic thromboembolic pulmonary hypertension
IPAH  Idiopathic pulmonary arterial hypertension
PH  Pulmonary hypertension
In precapillary pulmonary hypertension (PH) pulmonary vascular remodeling leads to high pulmonary arterial 
pressure, right ventricular failure and  death1. PH may develop in patients with systemic autoimmune and infec-
tious disorders, in chronic thromboembolic pulmonary disease (CTEPH), or in familial or idiopathic pulmonary 
arterial hypertension (IPAH).
In recent years, inflammation has been identified as a major driver of the pulmonary vascular remodeling 
contributing to the development of precapillary  PH2,3. Inflammatory cells such as T-cells and monocytes interact 
with pulmonary vascular cells and macrophages to generate vascular remodeling in the lungs of PH  patients4. 
The inflammatory mediators that are released from these activated immune cells are elevated in plasma/serum 
in PH and correlate to the disease severity and  progression5,6. However, cytokines and chemokines frequently 
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circulate at low levels, just above the detection limit of the actual assay, which limit their analytical performance 
and discriminatory properties beyond established clinical markers. On the other hand, certain markers reflecting 
activation of various leucocyte subsets such as monocytes, T-cells and neutrophils, circulate at readily detectable 
levels, but have not been evaluated in PH, with a few  exceptions7,8.
We hypothesize that circulating markers of leukocyte activation, reflecting monocytes/macrophages (soluble 
[s]  CD1639,  sCD1410), T-cells (soluble interleukin 2 receptor [sIL-2R]/CD2511 and neutrophils (myeloperoxidase 
(MPO)12, neutrophil gelatinase-associated lipocalin (NGAL)13) activity would be elevated in patients with pre-
capillary PH. We assumed that these markers would reflect vascular resistance and cardiac function, and could 
give information on long-term prognosis in these patients.
Methods
Study population. We studied 106 patients with precapillary PH in New York Heart Association (NYHA) 
functional classes II–IV (Table  1). Precapillary PH was defined in accordance with international guidelines 
as a mean pulmonary artery pressure (MPAP) ≥ 25  mm Hg at rest, a pulmonary capillary wedge pressure 
(PCWP) ≤ 15 mmHg and a PVR > 3.0 Wood units (WU)14. Based on the same guidelines, the study population 
was divided into three clinical subgroups: (1) patients with idiopathic PAH (IPAH; n = 30); (2) patients with PAH 
related to associated conditions (APAH; n = 44) [connective tissue disease, n = 21; HIV infection, n = 3; portal 
hypertension, n = 7; congenital heart disease, n = 13] and (3) patients with CTEPH (n = 32). Occlusive throm-
boembolic disease was verified with pulmonary angiograms. For comparison, we studied 23 healthy controls 
with CRP levels within normal limits. The investigation conforms to the principles outlined in the Declaration 
of Helsinki. The Regional Committee for Medical Research Ethics of Southern Norway approved the study, and 
informed consent was obtained from each subject.
Hemodynamics and cardiopulmonary exercise testing. Right-sided cardiac catheterization was per-
formed with a thermodilution catheter inserted through the right jugular vein, with a catheter inserted into the 
right femoral artery for the monitoring of arterial blood pressure and blood gases. Hemodynamic measurements 
included heart rate and right atrial pressure (RAP), mean pulmonary artery pressure (MPAP), and pulmonary 
capillary wedge pressure (PCWP). Cardiac output was calculated as the mean of three thermodilution technique 
measurements. We calculated pulmonary vascular resistance (PVR) and cardiac index (CI). Oxygen saturation 
was measured in blood samples from the femoral  (FaSO2) and pulmonary arteries  (PaSO2). Within 24 to 48 h 
of right-sided cardiac catheterization, a symptom-limited exercise test was performed using a cycle ergometer 
(ER900; Jäger, Wurzburg, Germany) with a steady cadence of 60 rotations per minute. The work-load started at 
Table 1.  Characteristics of the study group. APAH associated pulmonary arterial hypertension; CTEPH, 
chronic thromboembolic pulmonary hypertension;  FaSO2, Femoral artery oxygen saturation; IPAH, idiopathic 
pulmonary arterial hypertension; MPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal pro-
brain natriuretic peptide;  PaSO2, Pulmonary artery oxygen saturation; PCWP, pulmonary capillary wedge 
pressure; RAP, right atrial pressure; PVR, pulmonary vascular resistance; eGFR, estimated glomerular filtration 
rate; SpD, surfactant protein D. Data are presented as mean (SD) for continuous data and as percentage for 
categorical data. The medications represent therapy at baseline at the time of blood sampling. The p-value 
to the right represents the test for trend determined by Kruskal Wallis (continuous data) or chi-square 
(categorical data). p* < 0.05 versus IPAH, p† < 0.05 APAH versus CTEPH.
IPAH (n = 30) APAH (n = 44) CTEPH (n = 32) p-value
Age, year 43.1 (14.9) 44.2 (13.7) 56.7 (12.6)*† < 0.001
Sex, male 23% (7) 27% (12) 50% (16)*† 0.047
RAP, mm Hg 6.8 (4.2) 6.0 (4.6) 5.8 (3.6) 0.672
MPAP, mm Hg 55 (13) 51 (16) 42.7 (10.6)*† 0.001
PCWP, mmHg 6.5 (3.7) 6.1 (3.0) 7.0 (3.1) 0.483
Cardiac index, L/min/m2 1.8 (0.4) 2.2 (0.6)* 2.2 (0.7)* 0.002
PaSO2, % 58 (8) 59 (11) 62 (9) 0.204
FaSO2, % 94.3 (3.1) 90.9 (6.5)* 91.0 (4.5) 0.007
PVR, wood units 15.9 (5.5) 13.1 (6.3)* 9.3 (4.4)*† < 0.001
Peak VO2, ml/kg/min 12.0 (4.2) 12.9 (5.3) 13.3 (4.8) 0.515
NT-proBNP, pmol/L 341 (266) 297 (312) 185 (175)* 0.049
Creatinine (µmol/L) 95 (40) 85 (27) 90 (16) 0.085
eGFR (ml/min/1.73  m2) 71.7 (24.3) 80.8 (25.0) 72.9 (13.0) 0.224
CRP (mg/L) 4.7 (2.4, 6.6) 5.0 (2.8, 7.0) 3.4 (2.0, 5.5) 0.106
SpD (ng(/mL) 16.7 (8.1, 27.4) 24.4 (11.5, 48.3)* 29.8 (14.4, 36.0)* 0.038
PDE-5 inhibitor 50% (15) 50% (22) 0 (0)*† < 0.001
Prostaglandin I2  (PGI2) 47% (14) 16% (7)* 3% (1)* < 0.001
Endothelin receptor antagonist 40% (12) 21% (9) 3% (1)*† 0.002
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20 Watts and was raised incrementally 5–10 W per minute. Peak oxygen uptake (peak  VO2) was defined as the 
highest 30-s average of the oxygen uptake during the last minute of exercise.
Blood sampling and biochemical analyses. Blood samples were collected from the pulmonary artery 
(PH patients), femoral artery (PH patients), and peripheral vein (healthy controls) in chilled, pyrogen-free 
EDTA tubes. Platelet-free plasma (centrifuged within 30 min at 2000g for 20 min) was stored in multiple ali-
quots at – 80 °C until analyses and thawed once only prior to biochemical analysis. sCD25, sCD14, sCD163, 
MPO, NGAL, CRP and Surfactant protein D (SpD) were analyzed in duplicate by enzyme immunoassays from 
R&D Systems (Minneapolis, MN, USA). For sCD14 measurements, 20% fetal calf serum (Thermo Fisher Sci-
entific Inc, Waltham, MA, USA) were used in the sample diluent. N-terminal pro B-type natriuretic peptide 
(NT-proBNP) was determined by an electrochemiluminescence immunoassay on a Modular platform (Roche 
Diagnostics, Basel, Switzerland). All intra- and inter-assay coefficients of variation were < 10%.
Statistical analysis. Differences between groups were tested using Mann–Whitney U test (2 groups) or 
Kruskal–Wallis test (> 2 groups). Differences in the distribution of categorical data were analyzed with chi-
square test. Skewed markers of leucocyte activation were log transformed before analyses. Because the age and 
gender distribution differed between controls and patients, and across diagnostic categories of precapillary PH, 
group differences were compared by MANCOVA with age and sex as covariates and in some analysis also CRP 
and SpD. We performed Bonferroni-adjusted post-hoc tests. Changes in leucocyte markers over time were ana-
lyzed by the Wilcoxon paired test. Differences in changes in leucocyte markers between survivors and non-
survivors were analyzed by comparing change values (Mann–Whitney U test). Associations between leucocyte 
markers and clinical and hemodynamic parameters were assessed by Spearman correlation.
The association between leucocyte markers and all-cause mortality were assessed by multivariable Cox pro-
portional hazards models. Prior to analyses, the plasma concentrations of the leucocyte markers were normal-
ized, i.e. ln-transformed and divided by standard deviations. For assessment of the prognostic value of baseline 
levels, two models, with incremental addition of co-variates, were used in addition to univariate analysis. Model 
1 included age, sex, RAP,  PaSO2, estimated glomerular filtration rate (eGFR), CI, CRP and NT-proBNP (as the 
strongest predictors in univariate analysis) and Model 2 added peak  VO2. A propensity score was calculated based 
on these variables (without  peakVO2). Propensity score adjustment was used when evaluating survival within 
etiologies (due to low numbers). Results are presented as adjusted hazards ratios (HRs) and 95% confidence inter-
vals (CIs). Kaplan–Meier curves were constructed to visualize and evaluate (log rank test) differences in survival 
according to tertiles of leucocyte markers. Two-sided probability values were considered significant at p < 0.05.
Results
Characteristics of the study population are shown in Table 1. Patients with CTEPH were older, more frequently 
male, had lower MPAP and PVR, and used less medication than patients with IPAH and APAH. The healthy 
controls (n = 23) were older (59 ± 8 vs. 48 ± 15, p < 0.001) than the patients, and fewer were males (28% vs. 65%, 
p = 0.016).
Circulating leucocyte markers in plasma are elevated in precapillary pulmonary hyperten-
sion. Adjusted for age and sex, patients with APAH and CTEPH had elevated mixed venous blood (pul-
monary artery) levels of sCD25 and patients with IPAH and APAH had elevated mixed venous blood levels of 
sCD163 compared with peripheral venous levels in controls (Fig. 1). All the diagnostic groups had higher age 
and sex adjusted levels of sCD14, MPO and NGAL compared to the healthy controls, although there were no sta-
tistical differences between the separate diagnostics PH groups. A similar pattern between patients and healthy 
Figure 1.  Levels of soluble markers of leukocyte activation in precapillary PH. Patients with PAH were 
classified as idiopathic PAH (IPAH, n = 30), associated PAH (APAH, n = 44), and chronic thromboembolic 
pulmonary hypertension (CTEPH, n = 32) and in healthy controls (CTR, n = 23). Data are given as estimated 
marginal means (ng/ml) adjusted for age and sex. P value represents the overall group effect. *p < 0.05, **p < 0. 01 
***p < 0.001 versus controls. †p < 0.05, ††p < 0.001 between etiologies.
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controls was found when comparing samples from arterial blood (femoral artery, patients) and samples from 
peripheral venous blood in healthy controls (Supplementary Figure S2).
Significant differences across the diagnostic groups included higher levels of sCD25 and sCD163 in APAH 
compared to IPAH, and higher levels of NGAL in APAH and IPAH compared to CTEPH.
sCD25 and NGAL correlate with markers of systemic and pulmonary inflammation. To probe 
if the leukocyte activation markers reflect systemic or pulmonary inflammation or are released from the pulmo-
nary circulation we correlated levels with markers of systemic (CRP) and pulmonary (SpD) inflammation. As 
shown in Supplementary Table S1, NGAL and sCD25 consistently correlated positively with both CRP and SpD 
while sCD163 correlated with CRP only. Thus, the differences in sCD25 and sCD163 and to some degree NGAL 
levels between patients (including sub-groups) and controls were markedly attenuated when adjusting for CRP 
levels (Supplementary Figure S1). A similar effect for sCD25 and NGAL was seen with alleviated differences 
between the groups when including SpD in the adjustment.
Different levels of leukocyte activation markers in mixed venous blood from the pulmonary artery compared 
to arterial blood from the femoral artery could indicate local “production”/activation in the lungs. However, there 
were no significant difference in the levels of the markers between mixed venous blood (i.e. pulmonary artery) 
and arterial blood (i.e. femoral artery) (Table 2).
Modest association between leucocyte markers, pulmonary pressures and cardiac func-
tion. In the patients with PH, we found modest associations between the markers of leucocyte activation 
and clinical and hemodynamic features. The findings were similar in arterial and mixed venous plasma (Sup-
plementary Table S1). MPAP correlated negatively with sCD25, RAP correlated positively with sCD163,  PaSO2 
correlated negatively with sCD25 and sCD163,  peakVO2 correlated negatively with sCD25, sCD14 and sCD163, 
eGFR correlated negatively with sCD25, sCD14 and NGAL, while NT-proBNP correlated positively with sCD25. 
Thus, although the correlations were rather modest, sCD163 showed an interesting pattern with a positive asso-
ciation with RAP and a negative association with PaSO2 without any associations with eGFR.
Evaluating the association in etiological subgroups revealed that the associations were stronger in the APAH 
group, in particular for sCD25 (Supplementary Table S2).
Independent association of sCD163 with all-cause mortality in PH. During follow-up (median 
90 months [range 0.5–193 months]) 67 of 106 patients died. As shown in the Kaplan Meier curves in Fig. 2, 
increasing pulmonary arterial plasma levels of sCD25, sCD163 and NGAL were associated with long-term, all-
cause mortality. Results from multivariable cox regression are shown in the forest plot on the right side of Fig. 2 
and complete survival data from femoral and pulmonary plasma are presented in Supplementary Table S3. After 
adjusting for age, sex and the strongest hemodynamic and biochemical predictors of long-term outcome  (PaSO2, 
RAP, CI, eGFR, NT-pro-BNP and CRP as shown in Supplementary Table S3) sCD163 and sCD25 were still 
associated with all-cause mortality. The addition of  peakVO2 to the model had little influence on the association 
between sCD163 and all-cause mortality, in contrast to sCD25 where the association with all-cause mortality 
was markedly attenuated and no longer associated with outcome. CRP was not associated with all-cause mor-
tality in multivariable analysis (HR = 0.71, p = 0.17) and did not influence the association between sCD163 and 
all-cause mortality. When evaluating associations within different etiologies and using a propensity score (i.e., 
without including  peakVO2) for adjustment, some patterns were revealed. As shown in Fig. 2, leukocyte markers 
Table 2.  Levels of soluble markers of leucocyte activation in plasma from the femoral (AF) and pulmonary 
(AP) artery in precapillary pulmonary hypertension at baseline, follow-up, and their change value during 
follow-up (median 4 months). *p < 0.05 versus baseline, †p < 0.05 AF versus AP.
Baseline Follow-up Change
sCD25
AF 0.45 (0.26, 0.74) 0.66 (0.27, 0.85)* 0.04 (− 0.04, 0.37)
AP 0.66 (0.29, 0.96) 0.64 (0.32, 0.89) 0.04 (− 0.03 0.39)
sCD163
AF 674 (493, 914) 651 (498, 854) − 10 (− 261, 168)
AP 675 (544, 892) 687 (552, 922) − 39 (− 193, 218)
sCD14
AF 1.93 (1.69, 2.23) 1.99 (1.60, 2.30) 0.03 (− 0.10, 0.18)
AP 1.95 (1.69, 2.28) 2.09 (1.60, 2.31) − 0.02 (− 0.14, 0.17)
MPO
AF 150 (105, 187) 143 (100, 188)  − 7 (− 46, 47)
AP 155 (105, 205) 149 (104, 181)  − 7 (− 43, 39)
NGAL
AF 64.9 (45.5, 91.5) 65.8 (46.2, 88.3) 4.02 (− 7.84, 17.9)
AP 59.0 (41.9, 91.0) 59.1 (46.0, 95.6) 5.16 (− 10.7, 19.1)
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in the pulmonary artery, sCD25 was associated with poor prognosis in APAH only, while sCD163 were associ-
ated (not significant) with poor prognosis in IPAH.
Change in levels of leucocyte markers and all-cause mortality. Follow-up samples (median 
4 months, range 1–31 months) were obtained in 49 (46%) of the patients. Of these, 28 died (57%) during a 
median of 108 months follow-up (range 4–186 months). As shown in Supplementary Table S4, there were no 
significant differences in the changes in leukocyte markers between survivors and non-survivors. In the popula-
tion without a follow-up sample, 39 died (68%). Supplementary Table S5 details the difference in change in bio-
chemical and hemodynamic features between survivors and non-survivors during 4 month follow-up. A smaller 
decline in MPAP, PVR and CRP and a smaller increase in CI were observed in non-survivors.
Discussion
Our results demonstrate that (1) there is a systemic increase in soluble activation markers of different leucocyte 
subsets, in particular those reflecting monocyte and T-cell activation, in precapillary PH with mainly high levels 
in APAH (2) the monocyte/macrophage marker sCD163 was independently associated with poor long-term 
prognosis in the group as a whole (3) the T cell marker sCD25 was associated with poor prognosis in APAH, 
while sCD163 and the neutrophil marker NGAL were associated with poor prognosis in IPAH and CTEPH. 
Our data suggest that distinct patterns of leukocyte activation are associated with etiology and outcomes in 
precapillary PH. The association of sCD163, also after full adjustment, in the patient group as a whole is of 
particular interest.
The excessive vascular remodeling in pulmonary hypertension is associated with infiltration of inflamma-
tory cells, including T cells and monocytes/macrophages. Our study suggests that this activation is reflected 
Figure 2.  Soluble markers of leukocyte activation and all-cause mortality in precapillary pulmonary 
hypertension. (A) Left, Kaplan Meier curves showing associations between tertiles (ordered distribution into 
three parts, each containing a third of the cohort) (T1–T3) of sCD25 and all-cause mortality in plasma obtained 
from the pulmonary artery, p-values are from the log-rank test. Right, uni (blue) and multivariable (red, 
adjusting for age, sex, CI, RAP,  PaSO2, eGFR, CRP, NT-proBNP; green, as for red + peak  VO2) cox regression 
showing hazard ratios (HR), 95% CI and p-values for sCD25 in the whole patient population and according 
to etiology. IPAH, idiopathic pulmonary hypertension; APAH, acquired pulmonary hypertension; CTEPH, 
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by markers of systemic activation showing higher levels of sCD163 and sCD25 with particularly high levels in 
patients with APAH. We observed no difference in level of any marker between plasma obtained from mixed 
venous blood from the pulmonary artery versus arterial blood from the femoral artery indicating that the markers 
do not reflect accumulation, release or activation in the pulmonary circulation. Furthermore, sCD25, sCD163 and 
NGAL, representing the markers most closely associated with poor prognosis, correlated with CRP as a measure 
of systemic inflammation indicating they partly reflect a general state of enhanced inflammation. However, while 
CRP itself gave prognostic information, CRP did not influence the association between leukocyte activation 
markers and poor prognosis, suggesting these markers do not merely reflect enhanced systemic inflammation. 
Indeed, both sCD25 and NGAL correlated positively with SpD as a measure of pulmonary  inflammation15.
Elevated sCD163 has previously been reported in 26 patients with stable  PAH7 and in systemic sclerosis, 
where it correlated with right-sided cardiac function and disease  progression16. A major finding in the present 
study was that sCD163 was independently associated with poor outcome also after full adjustment of established 
hemodynamic markers, kidney function, NT-proBNP and  peakVO2. In subanalysis, the prognostic value of 
sCD163 seemed to be restricted to IPAH. Since increased sCD163 levels are observed in autoimmune diseases 
driven by activated  macrophages17–19 and autoimmune disease is a major component of APAH, the enhanced 
sCD163 levels in these patients may possible be secondary to their systemic disorders, and less implicated in 
progression of PH and poor prognosis. Moreover, perivascular infiltration of macrophages in pulmonary vas-
cular lesions have also been observed in patients with  IPAH20 and  CTEPH21, and the stronger association with 
prognosis in these patients, may suggest that systemic levels to a larger degree reflect monocyte/macrophage 
activation in pulmonary tissues in IPAH in patients. Elevated sCD163 is released by proteolysis during active 
 inflammation22, and it has also been suggested that sCD163 reflect the degree of activation of the pro-resolving 
and anti-inflammatory M2-like  macrophages23. However, whereas enhanced release of pro-resolving media-
tors could be beneficial, enhance release of for example transforming growth factor-β, a major product of M2 
macrophages, could promote PAH rather than resolve  it5. In fact, it has been suggested that M2 macrophages 
predominate in the progression of PAH and may associate with pulmonary vascular  remodeling24. Similar to 
sCD163, sCD14 was elevated in PAH but displayed no difference according to etiology. Ranchoux et al. also 
detected elevated sCD14 in PAH with no differences between iPAH and heritable PAH and linked the elevated 
levels to bacterial translocation and gut-lung  interactions25. Possibly, this could explain the different association 
with regard to etiology between sCD163 and sCD14 as well as the different association with prognosis.
In contrast to sCD163 that was not associated with poor outcome in APAH, the T cell marker sCD25 was 
significantly associated with poor prognosis in this PH subgroup. Dysregulated T cell numbers and function has 
frequently been reported in all forms of  PAH20,26–30, and contribute to the development and the progression of the 
disease. The present study, however, is to the best of our knowledge, the first report of raised levels of the general 
T-cell marker sCD25 in PH with particularly high levels in APAH. In relateion to the T-cells in PH, particular 
focus has been directed against abnormalities of regulatory T-cells (Treg) where increased systemic  levels27, but 
reduced numbers in the lungs of PAH patients has been  shown20. Deficient Treg cell activity in the lungs could 
blunt the response to inflammatory endothelial injury, including the pathogenic response of Th17 cells, thereby 
promoting PAH  progression30. Since sCD25 reflects overall T-cell activation and not particular subsets, it is not 
known if elevated levels reflect high Th17/Treg ratios. However, sCD25 has been shown to directly enhance Th17 
responses through its ability to sequester IL-2 and inhibit signaling downstream of IL-2R31 and could potentially 
be a mediator and not only a marker of T cell dysregulation in precapillary PH. Cause of death in APAH is most 
frequently due to end-stage HF and patients are characterized by low MaxVO2, which also completely mitigated 
the predictive ability of sCD25 when included in the cox regression model. We therefore speculate that the 
association between sCD25 and these indices, as well as NT-proBNP, may suggest a role for activated T cells in 
the transition to end-stage HF in APAH, as shown in experimental HF  models32,33.
The circulating markers MPO and NGAL reflect neutrophil activation and were elevated in all etiologies with 
the highest levels in IPAH and APAH. Neutrophils produce a wide range of substances that could contribute to 
vascular remodeling and promote inflammation in  PH34. Recently, MPO has been implicated in the pathophysi-
ology of PH by demonstrating increased plasma MPO levels in two independent PAH cohorts and showing a 
mechanistic link between MPO and adverse pulmonary vascular function. Furthermore, MPO predicted adverse 
outcome although adjustment was restricted to NT-proBNP35. In contrast, we observed no association between 
MPO and poor prognosis, but found NGAL levels to predict all-cause mortality and similar to sCD163, these 
associations were stronger in IPAH and CTEPH. However, in addition to neutrophils, NGAL is also produced 
by injured nephron epithelia and is an emerging marker of acute kidney injury with prognostic impact in popu-
lations with cardio-renal  syndromes36. Indeed, impaired renal function is a frequent co-morbidity in PAH and 
predictor of  mortality37, linked to cardiac dysfunction rather than  PH38.
Hemodynamic measures are used to monitor disease course in PH and non-invasive options are of interest 
for risk assessment and management of patients. However, we observed no difference in change of any leuko-
cyte activation markers between survivors and non-survivors in our study during 4 months follow-up. Possibly, 
this time is too short for any changes in these leucocyte markers between survivors and non-survivors. Also, a 
substantial number of patients died without a follow-up sample and earlier sampling may have revealed differ-
ent temporal course of the markers related to outcome. Changes in hemodynamic variables were not markedly 
different between survivors and non-survivors and sCD25 and sCD163 had only modest associations to these 
measures so we would not expect the markers to follow hemodynamic measures. A multimarker approach using 
a combination of markers has been proposed in predicting prognosis of PH while a number of single biomarkers 
have been evaluated reflecting different pathological  pathways8,39. The lack of association between the leukocyte 
activation markers and more established indices of disease progression suggest they may reflect other important 
functions or mechanisms of the disease and could therefore potentially add value in a multimarker approach. 
The current state-of-art treatment in PAH seems not to target key features of pathogenesis. Understanding the 
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role of leukocyte activation relevant to PAH pathophysiology may discover new therapeutic tools, but our study 
also highlights that etiology of PAH may have to be considered during manipulation of immune responses.
The present study has some limitations such as a relatively low number of healthy controls that were not 
matched with the PAH patients with relation to age and gender. However, the comparisons between patients and 
controls were adjusted for these variables. Inclusion of control population with increased systemic inflammation 
like scleroderma, would give more information on if the elevated marker levels reflect inflammation in general 
or if they do relate to PH. Moreover, the data from this single center study will have to be confirmed in addi-
tional PH cohort. We did not isolate circulating immune cells from these patients, and were unable to perform 
flow cytometry, which could give important additional information regarding activation of leucocyte subsets. 
Nonetheless, our study demonstrates a general leukocyte activation in precapillary PH with different profiles and 
impact on prognosis according to etiology. The prognostic impact of sCD163 also in the fully adjusted model 
should be of particular interest.
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information file).
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